Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
Conditions
Keywords
localized unresectable adult primary liver cancer, advanced adult primary liver cancer, unresectable gallbladder cancer, unresectable extrahepatic bile duct cancer, adult primary hepatocellular carcinoma, cholangiocarcinoma of the gallbladder, cholangiocarcinoma of the extrahepatic bile duct, adult primary cholangiocellular carcinoma
Brief summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analogue in treating patients who have advanced liver and/or biliary cancer.
Detailed description
OBJECTIVES: * Determine the response rate in patients with advanced hepatobiliary carcinoma treated with rebeccamycin analogue. * Assess the toxicity associated with this drug in this patient population. * Evaluate the survival of this patient population treated with this drug. * Determine the pharmacokinetics of this drug in this patient population. OUTLINE: This is a partial dose-escalation study. Patients receive rebeccamycin analogue IV over 1 hour daily on days 1-5. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients are assigned to 1 of 2 cohorts according to hepatic dysfunction. (Cohort I closed to accrual as of 11/1/03.) * Cohort I (closed to accrual as of 11/1/03): Patients receive a fixed dose of rebeccamycin analogue. * Cohort II: Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Patients are followed every 3 months. PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 6-37 months.
Interventions
DRUGbecatecarin
Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue until the maximum tolerated dose (MTD) is determined.
Sponsors
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Study design
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of advanced hepatobiliary carcinoma not amenable to conventional surgery * Gall bladder carcinoma * Cholangiocarcinoma * Carcinoma of the ampulla * Hepatocellular carcinoma (eligible for cohort II only) * Measurable disease * No known brain metastases PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 Life expectancy: * At least 12 weeks Hematopoietic: * WBC at least 3,000/mm\^3 * Granulocyte count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Hemoglobin greater than 10 g/dL Hepatic: * Bilirubin less than 3 mg/dL * Cohort I (closed to accrual as of 11/1/03) * Bilirubin no greater than 1.5 mg/dL * AST no greater than 2.5 times upper limit of normal (ULN) * Cohort II * Bilirubin greater than 1.5 mg/dL and less than 3 mg/dL OR * Bilirubin no greater 1.5 mg/dL AND AST greater than 2.5 times ULN Renal: * Creatinine normal OR * Creatinine clearance at least 60 mL/min Cardiovascular: * No New York Heart Association class III or IV heart disease Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior chemotherapy for cholangiocarcinoma or hepatobiliary carcinoma Endocrine therapy: * Not specified Radiotherapy: * Not specified Surgery: * Not specified Other: * No concurrent combination antiviral therapy for HIV-positive patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine the response rate in patients with advanced hepatobiliary carcinoma treated with rebeccamycin analogue. | Patients are followed every 3 months. |
Secondary
| Measure | Time frame |
|---|---|
| Assess the toxicity associated with this drug in this patient population. | Patients are followed every 3 months. |
Countries
United States
Outcome results
None listed